The NIH Office of the Director, Office of Acquisitions, intends to award a firm-fixed-price purchase order on a non-competitive basis to the University of Alabama at Birmingham, Birmingham, AL, for research support to develop and validate circulating cell-free DNA as a blood-based biomarker of chlorine-induced acute lung injury. The work relies on the Matalon Laboratory’s sole-source validated murine chlorine inhalation injury model, mechanistic expertise, an actively enrolling aspiration pneumonitis biorepository as a human proxy cohort, collaboration with the NHLBI Laboratory of Precision Omics, and continuity with NIH R01 HL031197. These capabilities are stated to be unavailable from any other source and essential to the project’s feasibility. The acquisition is a Notice of Intent for a non-competitive combined synopsis/solicitation and is not set aside for small business. The applicable NAICS code is 541380, Testing Laboratories and Services, with a $19.0 million small business size standard, and the solicitation incorporates provisions and clauses through FAC 2026-01, effective 03/13/2026.